GH Research PLC Stock price
Compare with Peer Group
Is GH Research PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
GH Research PLC Stock Analysis
Analyst Opinions
17 Analysts have issued a GH Research PLC forecast:
Analyst Opinions
17 Analysts have issued a GH Research PLC forecast:
Don't miss a Thing! We will send you all news about GH Research PLC directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
GH Research PLC Stock News
Company Profile
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
| Head office | Ireland |
| CEO | Dr. Valcheva |
| Employees | 73 |
| Founded | 2021 |
| Website | www.ghres.com |


